David Stephen Shulman, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Osteosarcoma | 5 | 2024 | 897 | 1.640 |
Why?
|
Bone Neoplasms | 6 | 2024 | 2529 | 1.100 |
Why?
|
Sarcoma | 5 | 2023 | 1801 | 0.960 |
Why?
|
Sarcoma, Synovial | 1 | 2022 | 153 | 0.730 |
Why?
|
Receptor, trkA | 1 | 2020 | 159 | 0.650 |
Why?
|
SEER Program | 2 | 2022 | 1450 | 0.640 |
Why?
|
Nomograms | 1 | 2020 | 230 | 0.630 |
Why?
|
Bacillus | 1 | 2018 | 78 | 0.620 |
Why?
|
Neutropenia | 1 | 2018 | 885 | 0.440 |
Why?
|
Hematopoietic Stem Cell Transplantation | 4 | 2021 | 5672 | 0.400 |
Why?
|
Bacteremia | 1 | 2018 | 980 | 0.390 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2016 | 686 | 0.390 |
Why?
|
Child | 19 | 2024 | 80156 | 0.310 |
Why?
|
Bone Marrow Transplantation | 1 | 2016 | 2693 | 0.310 |
Why?
|
Neoplasms | 8 | 2021 | 22173 | 0.310 |
Why?
|
Cytomegalovirus Infections | 1 | 2015 | 831 | 0.310 |
Why?
|
Fever | 1 | 2015 | 1618 | 0.280 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2022 | 3639 | 0.280 |
Why?
|
Hematologic Neoplasms | 1 | 2018 | 1896 | 0.280 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 11742 | 0.250 |
Why?
|
Protein Kinase Inhibitors | 2 | 2023 | 5672 | 0.240 |
Why?
|
Child, Preschool | 11 | 2024 | 42230 | 0.240 |
Why?
|
Antineoplastic Agents | 4 | 2020 | 13642 | 0.230 |
Why?
|
Retrospective Studies | 13 | 2024 | 80646 | 0.230 |
Why?
|
Prognosis | 5 | 2022 | 29629 | 0.220 |
Why?
|
Off-Label Use | 2 | 2024 | 185 | 0.210 |
Why?
|
Graft vs Host Disease | 1 | 2015 | 3029 | 0.200 |
Why?
|
Adolescent | 14 | 2024 | 88324 | 0.200 |
Why?
|
Length of Stay | 1 | 2015 | 6426 | 0.180 |
Why?
|
Patient Readmission | 1 | 2015 | 3271 | 0.180 |
Why?
|
Desmoplastic Small Round Cell Tumor | 1 | 2020 | 33 | 0.180 |
Why?
|
Minors | 1 | 2020 | 58 | 0.170 |
Why?
|
Bone Marrow Neoplasms | 1 | 2020 | 101 | 0.170 |
Why?
|
Risk Assessment | 1 | 2020 | 23996 | 0.160 |
Why?
|
Gene Fusion | 1 | 2022 | 356 | 0.160 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2020 | 326 | 0.160 |
Why?
|
Lung Neoplasms | 1 | 2023 | 13382 | 0.160 |
Why?
|
Biliary Atresia | 1 | 2019 | 88 | 0.160 |
Why?
|
Leiomyosarcoma | 1 | 2022 | 422 | 0.150 |
Why?
|
Ribonuclease III | 1 | 2020 | 279 | 0.150 |
Why?
|
Industry | 1 | 2020 | 364 | 0.150 |
Why?
|
Vincristine | 1 | 2020 | 1036 | 0.150 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2020 | 629 | 0.150 |
Why?
|
Lymphoproliferative Disorders | 1 | 2021 | 531 | 0.140 |
Why?
|
Leukemia, Myeloid, Accelerated Phase | 1 | 2016 | 7 | 0.140 |
Why?
|
DEAD-box RNA Helicases | 1 | 2020 | 384 | 0.140 |
Why?
|
Herpesvirus 8, Human | 1 | 2019 | 255 | 0.140 |
Why?
|
Humans | 33 | 2024 | 761572 | 0.140 |
Why?
|
Facial Paralysis | 1 | 2021 | 346 | 0.140 |
Why?
|
Young Adult | 9 | 2024 | 59255 | 0.140 |
Why?
|
Blast Crisis | 1 | 2016 | 102 | 0.130 |
Why?
|
Sarcoma, Kaposi | 1 | 2019 | 374 | 0.130 |
Why?
|
Research Support as Topic | 1 | 2020 | 697 | 0.130 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2019 | 549 | 0.120 |
Why?
|
Drug Approval | 2 | 2019 | 814 | 0.120 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2021 | 612 | 0.120 |
Why?
|
Infant | 6 | 2021 | 36192 | 0.120 |
Why?
|
United States Food and Drug Administration | 2 | 2019 | 1664 | 0.110 |
Why?
|
Follow-Up Studies | 3 | 2020 | 39107 | 0.110 |
Why?
|
Poverty | 1 | 2024 | 2698 | 0.100 |
Why?
|
Radiotherapy | 1 | 2019 | 1499 | 0.100 |
Why?
|
Central Nervous System Neoplasms | 1 | 2020 | 916 | 0.100 |
Why?
|
Adult | 11 | 2023 | 221203 | 0.100 |
Why?
|
Neoplasms, Second Primary | 1 | 2019 | 1052 | 0.090 |
Why?
|
Medical Oncology | 2 | 2020 | 2321 | 0.090 |
Why?
|
Regression Analysis | 1 | 2020 | 6344 | 0.090 |
Why?
|
Cell Cycle Proteins | 1 | 2022 | 3449 | 0.090 |
Why?
|
Rural Health Services | 1 | 2014 | 384 | 0.090 |
Why?
|
Remission Induction | 1 | 2016 | 2397 | 0.090 |
Why?
|
Incidence | 3 | 2019 | 21355 | 0.090 |
Why?
|
Bone Marrow | 1 | 2020 | 2911 | 0.090 |
Why?
|
Forecasting | 1 | 2019 | 2928 | 0.080 |
Why?
|
Time Factors | 4 | 2020 | 39970 | 0.080 |
Why?
|
Genomics | 2 | 2023 | 5821 | 0.080 |
Why?
|
Age Factors | 3 | 2020 | 18398 | 0.080 |
Why?
|
Glioma | 1 | 2024 | 3455 | 0.080 |
Why?
|
Hedgehog Proteins | 1 | 2013 | 768 | 0.080 |
Why?
|
Male | 13 | 2024 | 360842 | 0.080 |
Why?
|
PTEN Phosphohydrolase | 1 | 2013 | 1115 | 0.070 |
Why?
|
Sequence Analysis, DNA | 1 | 2018 | 4740 | 0.070 |
Why?
|
Female | 12 | 2024 | 392686 | 0.070 |
Why?
|
Liver Transplantation | 1 | 2019 | 2330 | 0.070 |
Why?
|
Clinical Trials as Topic | 2 | 2020 | 8002 | 0.070 |
Why?
|
United States | 5 | 2024 | 72335 | 0.070 |
Why?
|
Prevalence | 1 | 2023 | 15732 | 0.070 |
Why?
|
Survival Analysis | 1 | 2018 | 10090 | 0.060 |
Why?
|
Treatment Outcome | 4 | 2020 | 64684 | 0.060 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2023 | 9280 | 0.060 |
Why?
|
Risk Factors | 2 | 2022 | 74213 | 0.060 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2013 | 2865 | 0.060 |
Why?
|
Infant, Newborn | 2 | 2021 | 26198 | 0.060 |
Why?
|
Hypoaldosteronism | 1 | 2001 | 7 | 0.050 |
Why?
|
Drug Dosage Calculations | 1 | 2020 | 117 | 0.040 |
Why?
|
Renin | 1 | 2001 | 641 | 0.040 |
Why?
|
Government | 1 | 2020 | 161 | 0.040 |
Why?
|
Prospective Studies | 2 | 2022 | 54426 | 0.040 |
Why?
|
Ganciclovir | 1 | 2019 | 252 | 0.040 |
Why?
|
Glioblastoma | 1 | 2013 | 3482 | 0.040 |
Why?
|
Academies and Institutes | 1 | 2020 | 318 | 0.040 |
Why?
|
Cancer Care Facilities | 1 | 2020 | 422 | 0.040 |
Why?
|
Postoperative Complications | 1 | 2019 | 15633 | 0.030 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2020 | 793 | 0.030 |
Why?
|
Leukemia, Myeloid | 1 | 2019 | 694 | 0.030 |
Why?
|
Herpesvirus 4, Human | 1 | 2021 | 1078 | 0.030 |
Why?
|
Cohort Studies | 1 | 2018 | 41493 | 0.030 |
Why?
|
Disease Progression | 2 | 2024 | 13510 | 0.030 |
Why?
|
Chi-Square Distribution | 1 | 2020 | 3416 | 0.030 |
Why?
|
Biopsy, Needle | 1 | 2019 | 1626 | 0.030 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2022 | 1609 | 0.030 |
Why?
|
Drug Industry | 1 | 2020 | 788 | 0.030 |
Why?
|
Ribosomal Protein S6 Kinases | 1 | 2013 | 203 | 0.030 |
Why?
|
Medically Underserved Area | 1 | 2014 | 254 | 0.030 |
Why?
|
Brain Neoplasms | 1 | 2013 | 9031 | 0.020 |
Why?
|
Rwanda | 1 | 2014 | 665 | 0.020 |
Why?
|
RNA | 1 | 2022 | 2726 | 0.020 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2020 | 2010 | 0.020 |
Why?
|
Paclitaxel | 1 | 2019 | 1732 | 0.020 |
Why?
|
Morpholines | 1 | 2013 | 581 | 0.020 |
Why?
|
Lymphoma | 1 | 2019 | 1901 | 0.020 |
Why?
|
Aminopyridines | 1 | 2013 | 573 | 0.020 |
Why?
|
Tissue Donors | 1 | 2019 | 2332 | 0.020 |
Why?
|
Biopsy | 1 | 2020 | 6766 | 0.020 |
Why?
|
Biphenyl Compounds | 1 | 2013 | 1007 | 0.020 |
Why?
|
Middle Aged | 2 | 2020 | 220920 | 0.020 |
Why?
|
Health Resources | 1 | 2014 | 935 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2020 | 10766 | 0.020 |
Why?
|
Databases, Factual | 1 | 2023 | 7967 | 0.020 |
Why?
|
Carcinoma | 1 | 2019 | 2330 | 0.020 |
Why?
|
Boston | 1 | 2020 | 9326 | 0.020 |
Why?
|
Risk | 1 | 2019 | 9610 | 0.020 |
Why?
|
Mice, Nude | 1 | 2013 | 3614 | 0.020 |
Why?
|
Mutation | 2 | 2022 | 30054 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2020 | 11121 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2013 | 3603 | 0.020 |
Why?
|
Research Design | 1 | 2020 | 6180 | 0.010 |
Why?
|
Dysautonomia, Familial | 1 | 1985 | 94 | 0.010 |
Why?
|
Registries | 1 | 2020 | 8224 | 0.010 |
Why?
|
Liver | 1 | 2019 | 7529 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2013 | 3713 | 0.010 |
Why?
|
Fludrocortisone | 1 | 2001 | 24 | 0.010 |
Why?
|
Developing Countries | 1 | 2014 | 2885 | 0.010 |
Why?
|
Fentanyl | 1 | 1985 | 434 | 0.010 |
Why?
|
Pyridines | 1 | 2013 | 2875 | 0.010 |
Why?
|
Mice | 2 | 2022 | 81533 | 0.010 |
Why?
|
Health Personnel | 1 | 2014 | 3335 | 0.010 |
Why?
|
Melanoma | 1 | 2019 | 5709 | 0.010 |
Why?
|
Oligonucleotides, Antisense | 1 | 2001 | 461 | 0.010 |
Why?
|
Introns | 1 | 2001 | 981 | 0.010 |
Why?
|
Anesthesia, General | 1 | 1985 | 1174 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2013 | 16986 | 0.010 |
Why?
|
Aldosterone | 1 | 2001 | 870 | 0.010 |
Why?
|
Animals | 2 | 2022 | 168467 | 0.010 |
Why?
|
Exons | 1 | 2001 | 2391 | 0.010 |
Why?
|
Heterozygote | 1 | 2001 | 2787 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 4575 | 0.010 |
Why?
|
Anti-Inflammatory Agents | 1 | 2001 | 1809 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2019 | 36429 | 0.010 |
Why?
|
Signal Transduction | 1 | 2013 | 23447 | 0.010 |
Why?
|
Heart Rate | 1 | 1985 | 4195 | 0.000 |
Why?
|
Blood Pressure | 1 | 1985 | 8481 | 0.000 |
Why?
|